/start
    
    Write a perfect professional academic email toSHANNON P. FORTIN ENSIGN, M.D., PH.D.with these biography and research interests and papers "Shannon P. Fortin Ensign, M.D., Ph.D., oversees a research program that aims to acquire a better understanding of gliomas, and use this knowledge to direct the development of new treatments. Her research is aimed at clarifying the molecular properties within these aggressive brain tumors that enable them to become resistant to current treatments.

Cancer cells that survive treatment and are able to continue growing will repopulate the malignant tumor. Dr. Fortin Ensign is currently investigating genes in these tumors that direct resistance to treatments. These studies will help guide personalized molecular-based treatment approaches for people with gliomas.

Focus areas
Cancer genomics and intratumoral heterogeneity. Gliomas are notoriously varied in appearance and cell biology function across regions of the tumor. Thus, a major focus is studying these tumors at a molecular level, with a focus on their regional properties and evolution over time. This will enable a better understanding of genetic drivers, where they reside within the tumor and how they lead to resistance to current treatments.
Resistance mechanisms to therapy. Treatment options are limited for gliomas. Dr. Fortin Ensign is studying the impact of current therapies on the molecular properties of gliomas in order to better understand potential tumor vulnerabilities. This will allow identification of potential new therapeutic targets for this disease.
Translational and pre-clinical target validation. Dr. Fortin Ensign studies the biology of genetic drivers of glioma behavior in both tumor tissue taken directly from gliomas and tumor cells cultured in the lab to identify genes that show promise for new treatments. This data will help design future clinical trials for people with gliomas.
Significance to patient care
An improved understanding of the biology of gliomas will better direct targeted treatment strategies to improve patient outcomes for this disease. The aim is for findings from this research to be translated into clinical trial options for patients.

Professional highlights
Mayo Brothers Distinguished Fellowship Award, 2022
PROFESSIONAL DETAILS
Primary Appointment
Senior Associate Consultant, Division of Hematology/Oncology, Department of Internal Medicine
Joint Appointment
Senior Associate Consultant, Cancer Biology, Department of Research
Academic Rank
Assistant Professor of Medicine
EDUCATION
Chief Fellow
Hematology/Oncology Fellowship, Internal Medicine, Programs in Arizona, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
Fellow
Hematology/Oncology Fellowship, Internal Medicine, Programs in Arizona, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine
Chief Resident - Internal Medicine
Department of Internal Medicine, Scripps Green Hospital Graduate Medical Education
Residency - Internal Medicine
Department of Internal Medicine, Scripps Green Hospital Graduate Medical Education
MD - Medicine
University of Arizona College of Medicine - Phoenix
Ph.D. - Cancer Biology
University of Arizona/Translational Genomics Research Institute
Fulbright Scholar - Fellowship
Université Libre de Bruxelles
BS - Biochemistry
Arizona State University
Blomquist MR, Eghlimi R, Beniwal A, Grief D, Nascari DG, Inge L, Sereduk CP, Tuncali S, Roos A, Inforzato H, Sharma R, Pirrotte P, Mehta S, Fortin Ensign SP, Loftus JC, Tran NL. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma. Int J Mol Sci. 2024 Jun 6; 25 (11) Epub 2024 June 06
View PubMed
Gaulin C, Craig F, Fortin Ensign S, Robetorye R, Gibson S, Kelemen K, Khera N, Leis J, Tsang M, Rosenthal A, Munoz J, Palmer J, Hilal T. Allogeneic hematopoietic stem cell transplantation in adults with dendritic/histiocytic neoplasms. Leuk Lymphoma 2023 Dec; 64 (14):2347-2350 Epub 2023 Sept 07View PubMed
Huff D, Fortin Ensign S, Ryan MS, Palmer J, Munoz J. Histiocytic Sarcoma Treated with Pembrolizumab: A Case Report and Literature Review. J Immunother Precis Oncol. 2023 Nov; 6 (4):198-202 Epub 2023 Dec 02
View PubMed
Hu LS, D'Angelo F, Weiskittel TM, Caruso FP, Fortin Ensign SP, Blomquist MR, Flick MJ, Wang L, Sereduk CP, Meng-Lin K, De Leon G, Nespodzany A, Urcuyo JC, Gonzales AC, Curtin L, Lewis EM, Singleton KW, Dondlinger T, Anil A, Semmineh NB, Noviello T, Patel RA, Wang P, Wang J, Eschbacher JM, Hawkins-Daarud A, Jackson PR, Grunfeld IS, Elrod C, Mazza GL, McGee SC, Paulson L, Clark-Swanson K, Lassiter-Morris Y, Smith KA, Nakaji P, Bendok BR, Zimmerman RS, Krishna C, Patra DP, Patel NP, Lyons M, Neal M, Donev K, Mrugala MM, Porter AB, Beeman SC, Jensen TR, Schmainda KM, Zhou Y, Baxter LC, Plaisier CL, Li J, Li H, Lasorella A, Quarles CC, Swanson KR, Ceccarelli M, Iavarone A, Tran NL. Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures. Nat Commun. 2023 Sep 28; 14 (1):6066 Epub 2023 Sept 28
View PubMed
Ensign SF, Agarwal M, Klanderman M, Badawy M, Halfdanarson TR, Johnson DR, Sonbol MB, Kendi AT. Clinical utility of somatostatin receptor positron emission tomography imaging biomarkers for characterization of meningioma among incidental central nervous system lesions. Nucl Med Commun. 2023 Jul 1; 44 (7):663-670 Epub 2023 May 08
View PubMed
Fortin Ensign SP, Jenkins RB, Giannini C, Sarkaria JN, Galanis E, Kizilbash SH. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. Neuro Oncol. 2023 Jan 5; 25 (1):28-36
View PubMed
Thomson HM, Fortin Ensign SP, Edmonds VS, Sharma A, Butterfield RJ 3rd, Schild SE, Ashman JB, Zimmerman RS, Patel NP, Bryce AH, Vora SA, Sio TT, Porter AB. Clinical Outcomes of Stereotactic Radiosurgery-Related Radiation Necrosis in Patients with Intracranial Metastasis from Melanoma. Clin Med Insights Oncol. 2023; 17:11795549231161878. Epub 2023 Mar 21.
View PubMed
Fortin Ensign SP, Gaulin C, Hrachova M, Ruff M, Harahsheh E, Vicenti K, Castro J, Munoz J, Rosenthal A, Mrugala MM. Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. Curr Treat Options Oncol. 2022 Dec; 23 (12):1845-1860 Epub 2022 Dec 16
View PubMed
Fortin Ensign SP, Gathers D, Wiedmeier JE, Mrugala MM. Central Nervous System Lymphoma: Novel Therapies. Curr Treat Options Oncol. 2022 Jan; 23 (1):117-136 Epub 2022 Feb 19
View PubMed
Fortin Ensign SP, Yancey E, Anderson KS, Mrugala MM. Safety and Feasibility of Intrathecal Pembrolizumab Infusion in Refractory Triple Negative Breast Cancer with Leptomeningeal Disease: A Case Report. Current Problems in Cancer: Case Reports. 2021; 4:100103. Epub 2021 Jul 21.
Fortin Ensign S, Hrachova M, Chang S, Mrugala MM. Assessing the utility and attitudes toward molecular testing in neuro-oncology: a survey of the Society for Neuro-Oncology members. Neurooncol Pract. 2021 Jun; 8 (3):310-316 Epub 2021 Feb 17
View PubMed
Ding Z, Dong Z, Yang Y, Fortin Ensign SP, Sabit H, Nakada M, Ruggieri R, Kloss JM, Symons M, Tran NL, Loftus JC. Leukemia-Associated Rho Guanine Nucleotide Exchange Factor and Ras Homolog Family Member C Play a Role in Glioblastoma Cell Invasion and Resistance. Am J Pathol. 2020 Oct; 190 (10):2165-2176 Epub 2020 July 18
View PubMed
Fortin Ensign S, Bollin K, Millis SZ, Hinds BR, Kosty M, Uchiyama C. Genomic analysis reveals low tumor mutation burden which may be associated with GNAQ/11 alteration in a series of primary leptomeningeal melanomas. Pigment Cell Melanoma Res. 2020 May; 33 (3):458-465 Epub 2019 Dec 18"tell her that I adore her Both as a scientist and a woman that have been so much influential and also tell her that I really love to work and study under her guidance and write the letter with so much scientific notes that she learn that I have a lot of knowledge in this field also write her impressively and interestingly